A randomized controlled trial of cefiderocol versus standard therapy for Gram-negative bacterial bloodstream infections: Benefit and risk assessment using DOOR and generalized pairwise comparisons.

Hardy MJ, Harris PNA, Mo Y, Chatfield MD, Sulaiman H, Liu PY, Yilmaz M, Salmuna ZN, Mazlan MZ, Anunnatsiri S, Sirijatuphat R, Chotiprasitsakul D, Lye DC, Somani J, Kalimuddin S, Aslan AT, Thamlikitkul V, Lee YT, Yang YS, Lin YT, Cheng OH, Tseng CH, Archuleta S, Chan YFZ, Colaco CMG, Paterson DL, GAME CHANGER Trial Investigators

Open source

DOI: 10.1093/cid/ciag538
Published: 2026 Sep 7
Container: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1093/cid/ciag538,
  title = {A randomized controlled trial of cefiderocol versus standard therapy for Gram-negative bacterial bloodstream infections: Benefit and risk assessment using DOOR and generalized pairwise comparisons.},
  author = {Hardy MJ and Harris PNA and Mo Y and Chatfield MD and Sulaiman H and Liu PY and Yilmaz M and Salmuna ZN and Mazlan MZ and Anunnatsiri S and Sirijatuphat R and Chotiprasitsakul D and Lye DC and Somani J and Kalimuddin S and Aslan AT and Thamlikitkul V and Lee YT and Yang YS and Lin YT and Cheng OH and Tseng CH and Archuleta S and Chan YFZ and Colaco CMG and Paterson DL and GAME CHANGER Trial Investigators},
  year = {2026},
  journal = {Clinical infectious diseases : an official publication of the Infectious Diseases Society of America},
  doi = {10.1093/cid/ciag538},
  url = {https://doi.org/10.1093/cid/ciag538}
}

RIS

TY  - JOUR
TI  - A randomized controlled trial of cefiderocol versus standard therapy for Gram-negative bacterial bloodstream infections: Benefit and risk assessment using DOOR and generalized pairwise comparisons.
AU  - Hardy MJ
AU  - Harris PNA
AU  - Mo Y
AU  - Chatfield MD
AU  - Sulaiman H
AU  - Liu PY
AU  - Yilmaz M
AU  - Salmuna ZN
AU  - Mazlan MZ
AU  - Anunnatsiri S
AU  - Sirijatuphat R
AU  - Chotiprasitsakul D
AU  - Lye DC
AU  - Somani J
AU  - Kalimuddin S
AU  - Aslan AT
AU  - Thamlikitkul V
AU  - Lee YT
AU  - Yang YS
AU  - Lin YT
AU  - Cheng OH
AU  - Tseng CH
AU  - Archuleta S
AU  - Chan YFZ
AU  - Colaco CMG
AU  - Paterson DL
AU  - GAME CHANGER Trial Investigators
PY  - 2026
JO  - Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
DO  - 10.1093/cid/ciag538
UR  - https://doi.org/10.1093/cid/ciag538
ER  -

APA

MJ, H., PNA, H., Y, M., MD, C., H, S., PY, L., M, Y., ZN, S., MZ, M., S, A., R, S., D, C., DC, L., J, S., S, K., AT, A., V, T., YT, L., YS, Y., YT, L., OH, C., CH, T., S, A., YFZ, C., CMG, C., DL, P., & Investigators, G. C. T. (2026). A randomized controlled trial of cefiderocol versus standard therapy for Gram-negative bacterial bloodstream infections: Benefit and risk assessment using DOOR and generalized pairwise comparisons.. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. https://doi.org/10.1093/cid/ciag538

Source records

pubmed · retrieved 2026-09-25T08:34:59.599Z